Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference
Amarin Corporation plc (NASDAQ:AMRN) announced today that John F.
Thero, Amarin's president and chief executive officer, is scheduled
to present at the 39th Annual J.P. Morgan Healthcare Conference on
Tuesday, January 12, 2021 from 2:00 - 2:40 p.m. Eastern Time.
A live audio webcast of the presentation will be
available at: http://www.amarincorp.com and will be accessible at
the same link for 30 days.
Amarin Corporation plc is a rapidly growing,
innovative pharmaceutical company focused on developing and
commercializing therapeutics to cost-effectively improve
cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent
ethyl), is available by prescription in the United States, Canada,
Lebanon and the United Arab Emirates. VASCEPA is not yet approved
and available in any other countries. Amarin, on its own or
together with its commercial partners in select geographies, is
pursuing additional regulatory approvals for VASCEPA in China,
Europe and the Middle East. For more information about Amarin,
Availability of Other Information About
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (http://www.amarincorp.com/), the investor relations
website (http://investor.amarincorp.com/), including but not
limited to investor presentations and investor FAQs, Securities and
Exchange Commission filings, press releases, public conference
calls and webcasts. The information that Amarin posts on these
channels and websites could be deemed to be material information.
As a result, Amarin encourages investors, the media, and others
interested in Amarin to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. This list of channels may be updated from time to
time on Amarin’s investor relations website and may include social
media channels. The contents of Amarin’s website or these channels,
or any other website that may be accessed from its website or these
channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933.
InformationInvestor Inquiries:Investor RelationsAmarin
Corporation plcIn U.S.: +1 (908) 719-1315IR@amarincorp.com
Media Inquiries:CommunicationsAmarin Corporation
plcIn U.S.: +1 (908) 892-2028 PR@amarincorp.com (media